Tamoxifen and the risk of Parkinsonism: a case/non-case study

Tamoxifen and the risk of Parkinsonism: a case/non-case study Background Three studies have suggested a potential positive association between the use of tamoxifen in breast cancer and Parkinsonism, mainly after long-term exposure. Objectives To explore this potential signal, we performed a case/non-case study using the World Health Organization Global Individual Case Safety Reports (ICSRs) database, VigiBase® between 1979 and 2018. Methods Among women ≥ 55 years, we measured the risk of reporting BParkinsonism^ compared with all other adverse drug reactions [as a reporting odds ratio (ROR 95% CI)] for tamoxifen compared to all other drugs or aromatase inhibitors. Results During the study period, 356 ICSRs of Parkinsonism reported with tamoxifen were identified. We failed to find a positive association between tamoxifen exposure and Parkinsonism in comparison with exposure to other drugs (ROR = 0.79; 95% CI 0.71–0.88) or aromatase inhibitors (ROR = 0.39; 95% CI 0.33–0.46). Conclusion This study did not find evidence for Parkinsonism associated with tamoxifen. . . . . Keywords Tamoxifen Parkinsonism Adverse drug reaction Pharmacovigilance Drug safety Introduction breast cancer and risk of PD, mainly after long-term exposure [5–7]. The pharmacodynamic explanation of these findings Drug-induced Parkinsonism (DIP) is believed to be the second involves the well-known neuroprotective effects of estrogens cause of Parkinsonism http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Journal of Clinical Pharmacology Springer Journals

Loading next page...
 
/lp/springer_journal/tamoxifen-and-the-risk-of-parkinsonism-a-case-non-case-study-58mdMgoaq7
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer-Verlag GmbH Germany, part of Springer Nature
Subject
Biomedicine; Pharmacology/Toxicology
ISSN
0031-6970
eISSN
1432-1041
D.O.I.
10.1007/s00228-018-2496-3
Publisher site
See Article on Publisher Site

Abstract

Background Three studies have suggested a potential positive association between the use of tamoxifen in breast cancer and Parkinsonism, mainly after long-term exposure. Objectives To explore this potential signal, we performed a case/non-case study using the World Health Organization Global Individual Case Safety Reports (ICSRs) database, VigiBase® between 1979 and 2018. Methods Among women ≥ 55 years, we measured the risk of reporting BParkinsonism^ compared with all other adverse drug reactions [as a reporting odds ratio (ROR 95% CI)] for tamoxifen compared to all other drugs or aromatase inhibitors. Results During the study period, 356 ICSRs of Parkinsonism reported with tamoxifen were identified. We failed to find a positive association between tamoxifen exposure and Parkinsonism in comparison with exposure to other drugs (ROR = 0.79; 95% CI 0.71–0.88) or aromatase inhibitors (ROR = 0.39; 95% CI 0.33–0.46). Conclusion This study did not find evidence for Parkinsonism associated with tamoxifen. . . . . Keywords Tamoxifen Parkinsonism Adverse drug reaction Pharmacovigilance Drug safety Introduction breast cancer and risk of PD, mainly after long-term exposure [5–7]. The pharmacodynamic explanation of these findings Drug-induced Parkinsonism (DIP) is believed to be the second involves the well-known neuroprotective effects of estrogens cause of Parkinsonism

Journal

European Journal of Clinical PharmacologySpringer Journals

Published: Jun 3, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off